Is THC a Buy? What to Consider in 2026
Short answer
The bull case for Tenet Healthcare (THC) rests on USPI ambulatory surgery leadership: United Surgical Partners International is the largest ambulatory surgery center platform in the United States, with interests in more than 500 surgery centers and over two dozen surgical hospitals. Revenue (TTM) is ~$21.4 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. Whether THC is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Tenet Healthcare is a diversified for-profit healthcare services company that operates through three segments. Hospital Operations runs acute care and specialty hospitals plus affiliated outpatient facilities, imaging centers, and physician practices. United Surgical Partners International (USPI) is the ambulatory segment and operates or holds interests in hundreds of ambulatory surgery centers and surgical hospitals across dozens of states, making it the largest ASC platform in the country. Conifer Health Solutions provides revenue cycle management and value-based care services to hospitals and health systems. The investment story has shifted toward USPI, which benefits from the secular migration of surgical procedures out of expensive inpatient settings into lower-cost outpatient centers. USPI carries higher margins and grows faster than the hospital base, and Tenet has been acquiring additional surgery centers to expand it. Alongside that mix shift, management has cut debt, reduced interest expense, and earned credit-rating upgrades, which has lifted earnings per share and supported the stock. Founded in 1969 and headquartered in Dallas, Texas, Tenet trades on the NYSE and is a member of the S&P 500.
What's the case for buying THC?
1. USPI ambulatory surgery leadership.
United Surgical Partners International is the largest ambulatory surgery center platform in the United States, with interests in more than 500 surgery centers and over two dozen surgical hospitals. USPI grows faster and at higher margins than the hospital base and rides the multi-year shift of procedures from inpatient to outpatient settings. Same-facility surgical revenue and net revenue per case have been growing at healthy rates.
2. Business mix shift toward higher-margin services.
Tenet has sold hospitals and reinvested in USPI, tilting the revenue mix toward the higher-margin ambulatory business. This mix shift, combined with disciplined expense management and acquisitions of new centers, has expanded consolidated EBITDA margins well above historical hospital-operator norms.
3. Deleveraging and improved earnings quality.
Management has prioritized reducing debt, cutting interest expense, and returning capital through buybacks. Sustained deleveraging and EBITDA strength have driven credit-rating upgrades, and lower interest expense has compounded strong earnings-per-share growth over the past two years.
4. Conifer revenue cycle services.
Conifer Health Solutions provides revenue cycle management, patient communications, and value-based care support to hospitals and health systems, including Tenet's own facilities and third-party clients. It is a smaller, steadier services contributor that diversifies Tenet away from pure patient-care revenue.
What are the risks to THC?
Hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. Labor costs, physician and nurse staffing, and wage inflation weigh on the hospital segment. The company still carries meaningful debt despite deleveraging, so higher-for-longer interest rates matter. Bad debt from uninsured and underinsured patients, regulatory and billing scrutiny, and cyclicality in elective surgical volumes are additional risks. Acquisition-led USPI growth depends on continued access to attractive surgery-center deals at reasonable prices.
How is THC valued? (as of mid 2026)
Snapshot for THC as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$21.4 billion
- FY2025 net operating revenue: ~$21.3 billion (up ~3.7%)
- FY2025 adjusted diluted EPS: ~$16.78 (up ~41%)
- EBITDA margin: ~22-23%
- Net margin (TTM): ~12%
- Market cap: ~$18 billion
- P/E (TTM, adjusted): ~12x
- Dividend yield: None
Tenet trades at a modest earnings multiple typical of hospital operators, reflecting reimbursement and leverage risk, but the multiple has expanded from prior years as USPI mix shift, margin gains, and deleveraging improved earnings quality. The 2026 outlook calls for net operating revenue of roughly $21.5 to $22.3 billion. Figures are approximate and drawn from reported results and company guidance as of mid 2026.
How do you decide if THC is a buy?
Rather than asking whether THC is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold THC indirectly through an index or sector ETF before adding more.
For the full picture, see the THC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about THC against your real portfolio and see your actual exposure before deciding.
The bottom line on THC
The bottom line: Tenet Healthcare's story right now is USPI ambulatory surgery leadership, with revenue (ttm) at ~$21.4 billion. If you believe that narrative continues, the call is about sizing THC sensibly and checking overlap with what you own; if you doubt it (the risk: hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around THC with Walnut
Use Tenet Healthcare as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is THC a good stock to buy right now?
+
The case for Tenet Healthcare right now is USPI ambulatory surgery leadership, with revenue (ttm) at ~$21.4 billion. If you believe that thesis holds, THC is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Tenet Healthcare do?
+
Tenet Healthcare is a diversified for-profit healthcare services company that operates through three segments.
What are the main risks of THC?
+
Hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. Labor costs, physician and nurse staffing, and wage inflation weigh on the hospital segment. The company still carries meaningful debt despite deleveraging, so higher-for-longer interest rates matter. Bad debt from uninsured and underinsured patients, regulatory and billing scrutiny, and cyclicality in elective surgical volumes are additional risks. Acquisition-led USPI growth depends on continued access to attractive surgery-center deals at reasonable prices.
What is Tenet Healthcare's ticker symbol?
+
THC, listed on the New York Stock Exchange. Officially Tenet Healthcare Corporation, founded in 1969 and headquartered in Dallas, Texas. It trades during US market hours and is available at every major US brokerage, including as fractional shares at brokers that support them.
What does Tenet Healthcare do?
+
Tenet is a for-profit healthcare services company with three segments. Hospital Operations runs acute care and specialty hospitals plus affiliated outpatient facilities. United Surgical Partners International (USPI) operates the largest ambulatory surgery center platform in the United States. Conifer Health Solutions provides revenue cycle management and value-based care services to hospitals.
Who are Tenet Healthcare's competitors?
+
In hospitals, the main peers are HCA Healthcare, Community Health Systems, and Universal Health Services. In ambulatory surgery, Surgery Partners is the closest public comparable to USPI, and HCA also runs a large outpatient footprint. In revenue cycle services, Conifer competes with firms such as R1 RCM.
Is Tenet Healthcare in the S&P 500?
+
Yes. Tenet Healthcare is a member of the S&P 500 and is included in broad US and healthcare sector indices. That means index funds tracking the S&P 500, and healthcare-focused ETFs, hold THC as one of their constituents.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell THC; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.